60 Degrees Pharmaceuticals: Unlocking the Potential of Small Molecule Therapeutics

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. SXTP has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting COVID-19, fungal, tick-borne, and other viral diseases. Learn more at SXTPinfo.com.